HRP20160577T4 - Liječenje osteoartritisa - Google Patents

Liječenje osteoartritisa Download PDF

Info

Publication number
HRP20160577T4
HRP20160577T4 HRP20160577TT HRP20160577T HRP20160577T4 HR P20160577 T4 HRP20160577 T4 HR P20160577T4 HR P20160577T T HRP20160577T T HR P20160577TT HR P20160577 T HRP20160577 T HR P20160577T HR P20160577 T4 HRP20160577 T4 HR P20160577T4
Authority
HR
Croatia
Prior art keywords
antibody
intended
seq
amino acid
acid sequence
Prior art date
Application number
HRP20160577TT
Other languages
English (en)
Croatian (hr)
Inventor
John Allan Hamilton
Andrew David Cook
Original Assignee
The University Of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160577(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The University Of Melbourne filed Critical The University Of Melbourne
Publication of HRP20160577T1 publication Critical patent/HRP20160577T1/hr
Publication of HRP20160577T4 publication Critical patent/HRP20160577T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Polarising Elements (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
HRP20160577TT 2008-12-22 2009-12-21 Liječenje osteoartritisa HRP20160577T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US16448609P 2009-03-30 2009-03-30
EP09833924.5A EP2376121B2 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Publications (2)

Publication Number Publication Date
HRP20160577T1 HRP20160577T1 (hr) 2016-07-29
HRP20160577T4 true HRP20160577T4 (hr) 2021-08-20

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160577TT HRP20160577T4 (hr) 2008-12-22 2009-12-21 Liječenje osteoartritisa

Country Status (19)

Country Link
US (4) US9243061B2 (OSRAM)
EP (2) EP3056217B1 (OSRAM)
JP (3) JP5727379B2 (OSRAM)
KR (2) KR101898982B1 (OSRAM)
CN (2) CN106397591A (OSRAM)
AU (1) AU2009329814B2 (OSRAM)
BR (1) BRPI0918356B1 (OSRAM)
CA (1) CA2746827C (OSRAM)
CY (1) CY1117698T1 (OSRAM)
DK (1) DK2376121T4 (OSRAM)
ES (2) ES2572368T5 (OSRAM)
HK (1) HK1226938A1 (OSRAM)
HR (1) HRP20160577T4 (OSRAM)
HU (1) HUE028615T2 (OSRAM)
PL (1) PL2376121T5 (OSRAM)
RU (2) RU2011127334A (OSRAM)
SI (2) SI2376121T1 (OSRAM)
SM (1) SMT201600156B (OSRAM)
WO (1) WO2010071924A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
KR20150056846A (ko) 2012-09-20 2015-05-27 모르포시스 아게 류마티스 관절염에 대한 치료
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
KR20200054171A (ko) * 2017-08-14 2020-05-19 지네르바 파마슈티컬스, 인코포레이티드 경피 칸나비디올 겔을 이용한 골관절염의 치료 방법
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
EP0486572B1 (en) 1989-08-11 1998-01-07 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
US5747032A (en) 1990-08-10 1998-05-05 Amrad Corporation Limited Monoclonal antibody to human granulocyte macrophage colony stimulating factor
WO1994011404A1 (en) 1992-11-19 1994-05-26 Dana-Farber Cancer Institute Antibodies for gm-csf receptor and uses thereof
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
AU2002346882A1 (en) * 2001-10-26 2003-05-06 Novartis Ag Methods for the treatment of osteoarthritis and compositions thereof
ES2365606T3 (es) 2002-02-13 2011-10-07 Ludwig Institute For Cancer Research Ltd. Anticuerpos contra gm-csf quiméricos.
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
ES2341461T5 (es) 2004-02-11 2014-10-29 Warner-Lambert Company Llc Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
WO2006023412A2 (en) 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EP1874819B1 (en) 2005-04-18 2015-05-27 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
HUE058876T2 (hu) * 2005-05-18 2022-09-28 Morphosys Ag Anti-GM-CSF antitestek és felhasználásuk
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CA2629850A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
ES2609088T3 (es) * 2006-02-08 2017-04-18 Morphotek, Inc. Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF
RU2495050C2 (ru) * 2006-03-27 2013-10-10 Медимьюн Лимитед Связующий элемент для рецептора gm-csf
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
US20080206241A1 (en) * 2006-11-21 2008-08-28 Kalobios Pharmaceuticals Inc. Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
EP2160407A4 (en) * 2007-05-23 2011-07-27 Crc For Asthma And Airways Ltd NEUTRALIZING ANTIBODIES
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
US20100297135A1 (en) 2007-11-12 2010-11-25 Crc For Asthma And Airways Ltd. Epitope for neutralizing antibodies
PT2215119E (pt) * 2007-11-13 2013-02-11 Boehringer Ingelheim Int Anticorpos monoclonais que se ligam a hgm-csf e composições médicas que os compreendem
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
EP3056217B1 (en) 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
KR101761324B1 (ko) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies

Also Published As

Publication number Publication date
ES2572368T5 (es) 2021-12-16
EP2376121B2 (en) 2021-06-09
CN106397591A (zh) 2017-02-15
ES2572368T3 (es) 2016-05-31
CY1117698T1 (el) 2017-05-17
JP5727379B2 (ja) 2015-06-03
US20200247895A1 (en) 2020-08-06
JP2015143233A (ja) 2015-08-06
SMT201600156B (it) 2016-08-31
PL2376121T5 (pl) 2021-09-27
WO2010071924A1 (en) 2010-07-01
KR101898982B1 (ko) 2018-09-14
EP3056217A1 (en) 2016-08-17
RU2016102339A3 (OSRAM) 2019-07-29
BRPI0918356B1 (pt) 2022-03-08
HUE028615T2 (en) 2016-12-28
EP2376121A1 (en) 2011-10-19
HK1226938A1 (en) 2017-10-13
JP2017200933A (ja) 2017-11-09
AU2009329814A1 (en) 2010-07-01
EP2376121A4 (en) 2013-04-03
EP3056217B1 (en) 2021-06-30
KR101799264B1 (ko) 2017-11-20
DK2376121T3 (en) 2016-05-30
BRPI0918356A2 (pt) 2020-10-06
JP2012512815A (ja) 2012-06-07
KR20110128273A (ko) 2011-11-29
SI2376121T1 (sl) 2016-07-29
RU2011127334A (ru) 2013-01-27
RU2712273C2 (ru) 2020-01-28
DK2376121T4 (da) 2021-08-16
ES2886063T3 (es) 2021-12-16
US20120003234A1 (en) 2012-01-05
CA2746827C (en) 2018-01-23
CA2746827A1 (en) 2010-07-01
PL2376121T3 (pl) 2016-12-30
EP2376121B1 (en) 2016-03-09
CN102271705A (zh) 2011-12-07
US9243061B2 (en) 2016-01-26
SI2376121T2 (sl) 2021-11-30
JP6458086B2 (ja) 2019-01-23
US20160185868A1 (en) 2016-06-30
KR20170128630A (ko) 2017-11-22
HRP20160577T1 (hr) 2016-07-29
AU2009329814B2 (en) 2015-06-18
RU2016102339A (ru) 2018-11-21
US20180066062A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
HRP20160577T4 (hr) Liječenje osteoartritisa
HRP20211343T1 (hr) Protutijela protiv dkk-1
HRP20192233T1 (hr) Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
JP2011004758A5 (OSRAM)
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
ES2721753T3 (es) Anticuerpos contra IL-6 y usos de los mismos
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
HRP20171992T1 (hr) Protutijela protiv cgrp
CY1120417T1 (el) Μεθοδοι για τη μειωση των επιπεδων των βασεοφιλων
NZ605980A (en) Anti-fap antibodies and methods of use
NZ702494A (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NZ610734A (en) Human antibodies to the glucagon receptor
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ601271A (en) Cd127 binding proteins
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
EA035160B9 (ru) Антитела к st2 и их применение
RU2013135175A (ru) Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
WO2011103567A3 (en) Peptides and methods for inducing cell death
CN104245736A (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
WO2012018767A3 (en) Antibodies directed against il-17
EA201600088A1 (ru) Парентеральное введение тапентадола
JP2012025752A5 (OSRAM)
UA105520C2 (uk) Антитіла до людського tweak та їхнє застосування
UA107200C2 (uk) ОДИНИЧНИЙ ВАРІАБЕЛЬНИЙ ДОМЕН ІМУНОГЛОБУЛІНУ ПРОТИ РЕЦЕПТОРА ТИПУ 1 TNFα
ES2684173T3 (es) Anticuerpos anti-XCR1 humano